Brown Advisory Inc. Has $14.18 Million Stake in Insulet Co. (NASDAQ:PODD)

Brown Advisory Inc. trimmed its holdings in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 5.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 54,318 shares of the medical instruments supplier's stock after selling 2,915 shares during the quarter. Brown Advisory Inc. owned about 0.08% of Insulet worth $14,181,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of PODD. SBI Securities Co. Ltd. acquired a new position in Insulet in the fourth quarter valued at about $36,000. Itau Unibanco Holding S.A. acquired a new position in shares of Insulet in the 4th quarter valued at approximately $42,000. SRS Capital Advisors Inc. lifted its holdings in shares of Insulet by 43.1% during the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock worth $49,000 after acquiring an additional 56 shares during the period. Friedenthal Financial acquired a new stake in shares of Insulet during the 4th quarter worth approximately $57,000. Finally, Assetmark Inc. increased its stake in Insulet by 1,447.1% in the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock valued at $69,000 after acquiring an additional 246 shares during the last quarter.

Insider Activity at Insulet

In other Insulet news, Director Wayne A.I. Frederick sold 1,825 shares of the stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the transaction, the director now owns 3,231 shares in the company, valued at approximately $888,525. This represents a 36.10 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.47% of the stock is owned by corporate insiders.

Insulet Trading Up 20.8 %

Shares of PODD traded up $53.42 during trading hours on Friday, hitting $310.42. 3,214,360 shares of the stock were exchanged, compared to its average volume of 722,677. The firm has a market capitalization of $21.84 billion, a P/E ratio of 53.61, a price-to-earnings-growth ratio of 3.62 and a beta of 1.26. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $312.80. The business has a 50-day moving average of $257.45 and a 200-day moving average of $263.50.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.81 by $0.21. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The company had revenue of $569.00 million for the quarter, compared to the consensus estimate of $543.20 million. During the same period in the previous year, the business earned $0.73 EPS. The firm's revenue was up 28.8% compared to the same quarter last year. On average, research analysts expect that Insulet Co. will post 3.92 EPS for the current year.

Wall Street Analyst Weigh In

PODD has been the topic of a number of research analyst reports. Citigroup raised their target price on Insulet from $310.00 to $355.00 and gave the company a "buy" rating in a report on Friday, February 21st. Wolfe Research cut Insulet from an "outperform" rating to a "peer perform" rating in a research report on Tuesday, April 29th. Barclays increased their target price on shares of Insulet from $234.00 to $266.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 30th. Piper Sandler lifted their price target on shares of Insulet from $285.00 to $310.00 and gave the company an "overweight" rating in a report on Friday, February 21st. Finally, StockNews.com lowered shares of Insulet from a "buy" rating to a "hold" rating in a research report on Tuesday, March 4th. Five analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $301.24.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.